top of page

Customers We Serve

The solutions we offer harnesses complex machine learning and AI's potential in biotechnology to conduct in-depth technical analysis, surpassing prior limitations - de-risking investor capital.

In typical biotech investment presentations, researchers aim to understand causal relationships between variables like molecules and tissues. However, human cognitive biases can lead to flawed hypotheses and incorrect conclusions.


Current legal and financial due diligence practices often miss the full complexity of real-world biological interactions. Consequently, despite extensive due diligence, 90% of clinical drug development fails, resulting in significant losses for investors. These failures occur because investors lack the critical insights provided by Imagine Biotech's reports.

Venture Capital Funds/Private Investors

Amidst waning confidence and funding challenges faced by some biotech VC funds, we add sophisticated technical due diligence services to create real value. We offer scientific reports to evaluate and mitigate investment risks by early identification of drug-protein interaction and human physiology absorption  issues, enhancing decision-making efficiency and resource savings. Supporting funds as they set out to build investor confidence, and raise capital from limited partners.



We offer third party verification of their drug hypothesis or candidates' that should lead to easier risk adjusted investor interest. Assisting with efficient resource allocation, and data-driven decision-making, leveraging our team of experts. We aim to assist in de-risking the project, enhanced investor appeal, and improved project success prospects, while also ensuring regulatory compliance. 


Family Offices and Patient Groups

Family offices and patient groups that are working with single disease research, and support those who are considering funding the best solution efforts of a proposed cure.

Pink and Teal Llama Desk Strip.png

Get in touch with us through our contact form; we're here and ready to discuss possibilities in a different light.

bottom of page